Latest Conference Content

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL).

A unique targeted therapy, quizartinib, was able to clear leukemia cells from the bone marrow in more than 33% of patients with an aggressive form of acute myeloid leukemia marked by a mutation in the FLT3 gene.

Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.

An investigational, weekly, oral proteosome inhibitor called MLN9708 achieved excellent response rates when combined with lenalidomide and dexamethasone as up-front treatment of newly diagnosed patients with multiple myeloma, according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology.

Thomas P. Loughran, Jr, MD, Professor of Medicine, Penn State University, Director, Penn State Hershey Cancer Institute, describes the clinical sequelae of large granular lymphocyte (LGL) leukemia, particularly noting neutropenia and anemia, and discusses the pharmacotherapeutic approach.

Ibrutinib, an investigational Bruton's tyrosine kinase inhibitor, achieved excellent results in clinical trials of patients with chronic lymphocytic leukemia (CLL) presented at the 54th Annual Meeting of the American Society of Hematology.

Richard T. Hoppe, MD, Professor of Radiation Oncology - Radiation Therapy, Stanford School of Medicine, discussed the current role and utility of radiation therapy in patients with early stage Hodgkins Lymphoma when compared to conventional chemotherapy.

Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

"Health insurance exchanges are the first step in the consumerization of the healthcare marketplace," said David Brailer, MD, PhD, chairman, Health Evolution Partners.

An expanding retail marketplace means that there are more opportunities for health plans to develop innovative strategies to reach consumers that are entering the market space for the first time. It is essential for health plans to not only engage these consumers but also to assist them in making good healthcare decisions.

Ashish Jha, MD, MPH, associate professor of Health Policy and Management, Department of Health Policy and Management, Harvard School of Public Health, says that there are many challenges facing the quality of data used to transform healthcare delivery systems.

Gail Wilensky, PhD, senior fellow, Project Hope, says that larger payers are introducing plans that reward consumers for choosing high-quality healthcare clinicians with lower co-payments and premiums.

Incomprehensible amounts of data are collected by all sectors of the healthcare industry on a daily basis. It is important for organizations to not only understand how to handle and collect this data, but also to translate it into actionable information that can help transform healthcare delivery. Unfortunately, many pitfalls still exist, and there is a need for better processes to collect clinically relevant and more complete data.

Avik Roy, senior fellow, Manhattan Institute, says that health insurance exchanges will, over time, become the main method of delivering health insurance in the United States.

Tuesday morning at AHIP's Fall Forum 2012 included a session on the methods in which evolving technologies and disruptive innovations will undoubtedly lead to better and more cost-efficient patient care.

The America's Health Insurance Plans Fall Forum 2012 is taking place in Chicago's Renaissance Hotel from December 3-5. Here are some of the topics and trends that will be discussed.

Cindy Bjorkquist, Director of Wellness, Care Management and Health Promotion Programs Development, Blue Cross Blue Shield of Michigan, discusses Blue Cross Blue Shield of Michigan's Total Health Improvement Strategy.

Day 1 of the America's Health Insurance Plans Fall Forum 2012 featured a pre-conference workshop on patient engagement strategies to promote wellness in a consumer-driven marketplace. Presenter and moderator Jen Cressman, Vice President, Strategic Accounts, Krames StayWell, centered her discussion on the design of effective communication strategies and how to attract and engage consumers while also fostering loyalty.

Check out photos from America's Health Insurance Plans Fall Forum 2012. The meeting is being held at the Renaissance Hotel in Chicago, IL, from December 3-5.

Healthcare is in the midst of a shift toward more patient-centric and accountable care; as a result, time- and resource-constrained providers are embracing new and innovative models for delivering and organizing care.

Highlights from the Academy of Managed Care Pharmacy's 2012 Educational Conference, which took place on October 3-5, 2012, in Cincinnati, Ohio, are available in a newsletter published by The American Journal of Managed Care. Topics discussed include the ways in which heterogeneity shapes therapeutic decisions, patient outcomes, and coverage policies; assessment of the evidence for new medications; and phone-based medication therapy management services.

Check out photos from The American Journal of Managed Care's first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology," which took place on November 16. The meeting was held at the Hyatt Regency Inner Harbor in Baltimore, MD.

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.

Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.

Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.